[Translation] A randomized, open-label, single-dose, two-sequence, two-period, double-crossover bioequivalence pre-trial of octopapon capsules (50 mg) in healthy Chinese participants under fasting administration conditions.
主要研究目的:按有关生物等效性试验的规定,选择Bial-Portela & Ca., S.A.为持证商的奥匹卡朋胶囊(商品名:Ongentys®,规格:50mg)为参比制剂,对华润双鹤利民药业(济南)有限公司生产并提供的受试制剂奥匹卡朋胶囊(规格:50mg)进行空腹给药人体生物等效性预试验,比较两种制剂在中国健康试验参与者体内的药代动力学行为,评估两种制剂在空腹给药条件下生物等效性的可能性,为正式试验设计提供参考依据。
次要研究目的:观察健康试验参与者口服受试制剂奥匹卡朋胶囊(规格:50mg)和参比制剂奥匹卡朋胶囊(商品名:Ongentys®,规格:50mg)的安全性。
[Translation] Primary objective: In accordance with relevant bioequivalence testing regulations, octopaine capsules (trade name: Ongentys®, strength: 50mg), manufactured by Bial-Portela & Ca., S.A., was selected as the reference formulation. A pre-biological bioequivalence study was conducted on the test formulation octopaine capsules (strength: 50mg), manufactured and supplied by CR Double-Crane Pharmaceutical (Jinan) Co., Ltd., under fasting administration. The pharmacokinetic behavior of the two formulations in healthy participants in China was compared to assess the likelihood of bioequivalence under fasting administration conditions, providing a reference for the design of the formal trial.
Secondary objective: To observe the safety of oral administration of the test formulation octopaine capsules (strength: 50mg) and the reference formulation octopaine capsules (trade name: Ongentys®, strength: 50mg) to healthy participants.